Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Stem Cell Reviews and Reports is Scopus-indexed (Q1, CiteScore 9.6), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer.
Checked against the index lists dated .
ISSN 2629-3269Verify ISSN ↗2629-3277Verify ISSN ↗
Publisher: Springer
Cost to publish: About US$4,390 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Cell Biology | 61 / 289 | 79th | Q1 |
| Cancer Research | 52 / 233 | 77th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q1, CiteScore 9.6.
Stem Cell Reviews and Reports is Q1 in Cell Biology (rank 61 of 289) and Q1 in Cancer Research (rank 52 of 233), by CiteScore 2025.
Stem Cell Reviews and Reports is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 9.6, which places it in quartile Q1 at the 79th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.217, quartile Q2, with an H-index of 96.
The publisher lists an article processing charge of about US$4,390 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Stem Cell Reviews and Reports is published by Springer. Its print ISSN is 2629-3269 and its online ISSN is 2629-3277.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Stem Cell Reviews and Reports has an h-index of 111 and a 2-year mean of 4.27 citations per paper (OpenAlex). Its Scopus CiteScore is 9.6, quartile Q1. On 2-year citations it ranks #89 of 288 Scopus journals in Cell Biology.
Stem Cell Reviews and Reports published 208 papers in 2025; its busiest recent year was 2021 with 211. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 92 research articles (2026), authors are most often from China (51.6%), India (9.4%) and United States (6.2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (0.4 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.